SCHEMBL17069048

SCHEMBL17069048

CC(=O)N1CCC[C@H]1c1cnc(C)[nH]1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BAZ2A Q9UIF9 1/20 0.43
▸ CCNT1 O60563 1/20 0.42
▸ CDK9 P50750 1/20 0.42
▸ HCRTR1 O43613 4/20 0.41
▸ HCRTR2 O43614 4/20 0.41
▸ CYP3A4 P08684 3/20 0.40
▸ CYP2C9 P11712 3/20 0.40
▸ NR1I2 O75469 1/20 0.40
▸ ABCB11 O95342 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ TP53 P04637 3/20 0.39
▸ MAPT P10636 1/20 0.39
▸ CYP11B2 P19099 1/20 0.38
▸ PRCP P42785 2/20 0.37
▸ GCK P35557 2/20 0.37
▸ CYP1A2 P05177 2/20 0.36
▸ CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17069047 0.83 ALDH1A1 (0.47) TP53MAPT
SCHEMBL5993645 0.79 CYP3A4 (0.65) CYP3A4CYP2C9NR1I2ABCB11OPRK1
SCHEMBL17069044 0.78 CYP3A4 (0.46) BAZ2AHCRTR1HCRTR2CYP3A4CYP2C9
SCHEMBL17069041 0.76 BAZ2A (0.41) BAZ2ACCNT1CDK9CYP3A4CYP2C9
SCHEMBL17069039 0.71 HCRTR1 (0.41) BAZ2AHCRTR1HCRTR2TP53MAPT
SCHEMBL24015824 0.71 HTR2B (0.40) BAZ2ACCNT1CDK9CYP3A4CYP2C9
SCHEMBL24015823 0.71 RIPK1 (0.41) BAZ2ACCNT1CDK9TP53MAPT
SCHEMBL18596014 0.70 HCRTR1 (0.37) BAZ2AHCRTR1HCRTR2CYP3A4CYP2C9
SCHEMBL475038 0.69 ALDH1A1 (0.52) TP53MAPT
SCHEMBL903678 0.69 ALDH1A1 (0.52) TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493446-B2 Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2016-11-15 — — US disclosed
US-20150252032-A1 OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2015-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252032-A1 OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES HCRTR2, HCRTR1, OXTR BAZ2A 1768/4885CCNT1 1396/4885CDK9 2145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback